Search
for
Sort by
Research 211–240 of 1000+
- Sustaining treatment response in alopecia areata through tofacitinib dose tapering: A single-center retrospective study
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- Network pharmacology, molecular docking, and dynamics reveal the mechanisms of Hejie Shengfa Decoction against alopecia areata
- Towards cell-based therapy of alopecia areata: Autologous human Vδ2+ Foxp3+ γδTreg cells restore hair-follicle immune privilege and promote hair regrowth in human alopecia areata models ex vivo and in vivo
- Successful treatment of alopecia areata‐associated trachyonychia with baricitinib
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
- T <sub>H</sub> 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
- Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata
- Brave New World
- Nail Brace Application
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- Folliculin: A surprising molecular brake in the human hair follicle
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
- Herpes Zoster y COVID 19, coexistencia en un paciente no inmunodeprimido. Reporte de un caso y breve revisión a propósito del mismo.
- Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Fifty-six years of plastic surgery
- Foxn1 promotes keratinocyte differentiation by regulating the activity of protein kinase C
- Wear characteristics of epoxy based hybrid composites reinforced with short hair fibers and glass micro spheres
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
- Baricitinib regrows hair in adolescents with alopecia areata
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- The Hair Follicle as an Estrogen Target and Source
- 715 Hunting the hair cycle clock (HCC): Evidence that mitochondrially localized MPZL3 is a key HCC element in murine and human hair follicles